AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$TENX

Doogan Declan purchased $102K of TENX

Doogan Declan purchased 53,000 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.92 ($0.10M total) on 2026-09-16.

Original reporting
SEC EDGAR · Doogan Declan
Published Sep 18, 2026, 1:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TENX
Bullish
medium confidence
Mentioned
$TENX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TENXBullishLow
01

Why it matters

Director purchase suggests possible confidence but limited material impact.

02

Market read

Small insider purchase with modest relevance for traders monitoring insider activity.

03

What to watch

Potential upcoming clinical data not disclosed could be driving the purchase.

Relevance 5/10Novelty 5/10Timing: filing date 2026-09-17

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

$TENXBullishMedium confidence
Context

Director Doogan Declan bought 53,000 shares for $101,760, increasing his stake to 55,274 shares.

Expected impact

Slight upward pressure if market perceives confidence.

Evidence & confidence

Purchase size is modest but director-level buying can be viewed positively.

Market effects

Sector

May hint at confidence in biotech sector pipeline.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Insider buying could be routine portfolio rebalancing, not a strong signal.

Key entities

  • Company
    Tenax Therapeutics, Inc.

    Biotech firm listed under ticker TENX.

  • Insider
    Doogan Declan

    Director of Tenax Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TENX insider trading history →

Related articles

SEP 4
$TENXMedAI 8/10

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.

insidermonkey.com2 min
AUG 31
$TENXHighAI 9/10

Why is Tenax Therapeutics stock volatile today?

Tenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.

investing.com2 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

quiverquant.com3 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.

finance.yahoo.com2 min